Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: Results from the boston area community health survey

American Journal of Epidemiology

Volumn 173, Issue 9, 2011, Pages 1022-1031

  Gates, Margaret A ^a   Hall, Susan A ^a   Chiu, Gretchen R ^a   Kupelian, Varant ^a   Fitzgerald, Mary P ^b   Link, Carol L ^a   McKinlay, John B ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

analgesics; anti inflammatory agents; cyclooxygenase 2 inhibitors; nocturia; non steroidal; urination disorders

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ABNORMALITY; BONE; CONFIDENCE INTERVAL; DISEASE INCIDENCE; DRUG USER; ENZYME ACTIVITY; ETIOLOGY; HEALTH SURVEY; INHIBITOR; REGRESSION ANALYSIS; SYMPTOM; URINE; WOMENS HEALTH;

ADULT; ARTHRITIS; ARTICLE; COMMUNITY ASSESSMENT; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICTURITION; NOCTURIA; PRESCRIPTION; SEX DIFFERENCE; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BOSTON; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NOCTURIA; NONPRESCRIPTION DRUGS; PRESCRIPTION DRUGS; URINATION DISORDERS;

EID: 79955583965     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq473     Document Type: Article

References (41)

1. Kupelian V, Wei JT, O'Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006; 166(21):2381-2387. (Pubitemid 44833365)
2. Kupelian V, McVary KT, Barry MJ, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health Survey. Urology. 2009;73(5):950-957.
3. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62(1): 27-33. (Pubitemid 39614290)
4. St Sauver JL, Sarma AV, Jacobson DJ, et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009;169(11):1281-1290.
5. St Sauver JL, Jacobsen SJ. Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. Curr Prostate Rep. 2008;6(2):67-73.
6. Gruenenfelder J, McGuire EJ, Faerber GJ. Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors [case report]. J Urol. 2002;168(3):1106.
7. Verhamme KM, Dieleman JP, Van Wijk MA, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med. 2005;165(13):1547-1551. (Pubitemid 41058037)
8. St Sauver JL, Jacobson DJ, McGree ME, et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164(8):760-768. (Pubitemid 44522080)
9. Araki T, Yokoyama T, Araki M, et al. A clinical investigation of the mechanism of loxoprofen, a non-steroidal antiinflammatory drug, for patients with nocturia. Acta Med Okayama. 2008;62(6):373-378.
10. Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama. 2004;58(1):45-49. (Pubitemid 38406283)
11. Cardozo LD, Stanton SL. A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. J Urol. 1980;123(3):399-401. (Pubitemid 10068964)
12. Cardozo LD, Stanton SL, Robinson H, et al. Evaluation of flurbiprofen in detrusor instability. Br Med J. 1980;280(6210): 281-282. (Pubitemid 10213080)
13. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(1):72-78; discussion 78-79.
14. Kang D, Andriole GL, Van De Vooren RC, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004; 93(9):1241-1245. (Pubitemid 38823945)
15. McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52(2):389-396. (Pubitemid 46963446)
16. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. Correlation of the American Urological Association symptom index with selfadministered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1558-1563; discussion 1564.
17. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557; discussion 1564.
18. Bad́a X, Garća-Losa M, Dal-Ré R, et al. Validation of a harmonized Spanish version of the IPSS: evidence of equivalence with the original American scale. International Prostate Symptom Score. Urology. 1998;52(4):614-620.
19. Chai TC, Belville WD, McGuire EJ, et al. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol. 1993;150(5 pt 2):1710-1713. (Pubitemid 24346930)
20. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventynine years of age. Urology. 1993;42(1):36-40; discussion 40-41.
21. Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157(10): 906-914. (Pubitemid 36555050)
22. Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003; 92(9):948-954. (Pubitemid 37548272)
23. Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH Survey. J Urol. 2007;177(4):1385-1389. (Pubitemid 46436009)
24. Wheeler BW, Metcalfe C, Gunnell D, et al. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol. 2009;68(5): 752-764.
25. Litman HJ, Steers WD, Wei JT, et al. Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health Survey. Urology. 2007;70(5):916-921. (Pubitemid 350192576)
26. Green LW. Manual for scoring socioeconomic status for research on health behavior. Public Health Rep. 1970;85(9): 815-827.
27. Washburn RA, Smith KW, Jette AM, et al. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153-162. (Pubitemid 23092124)
28. Turvey CL,Wallace RB, Herzog R. A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr. 1999; 11(2):139-148. (Pubitemid 29325579)
29. Schafer JL. Analysis of Incomplete Multivariate Data. New York, NY: Chapman & Hall; 1997.
30. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24(1):33-50. (Pubitemid 46722293)
31. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84(9):976-981.
32. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43(2):164-175. (Pubitemid 36221971)
33. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202-1216. (Pubitemid 46436310)
34. Robert G, Descazeaud A, Nicoläew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69(16):1774-1780.
35. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE Trial. Eur Urol. 2008;54(6):1379-1384.
36. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS Study [abstract]. J Urol. 2005;173(suppl):346.
37. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61(1):60-72. (Pubitemid 39095695)
38. Verhamme KM, Sturkenboom MC, Stricker BH, et al. Druginduced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-388. (Pubitemid 351563730)
39. Park JM, Yang T, Arend LJ, et al. Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol. 1999;276(1 pt 2): F129-F136. (Pubitemid 29061733)
40. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54(9): 935-944. (Pubitemid 32771319)
41. Robertson C, Link CL, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int. 2007;99(2): 347-354. (Pubitemid 46103115)